Nano-scaled MTCA-KKV: For targeting thrombus, releasing pharmacophores, inhibiting thrombosis and dissolving blood clots in vivo

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Background: In vitro (1R,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxyl-Lys(Pro-Ala-Lys)-Arg-Gly-Asp-Val (MTCA-KKV) adheres activated platelets, targets P-selectin and GPIIb/IIIa. This led to the development of MTCA-KKV as thrombus targeting nano-medicine. Methods: MTCA-KKV was characterized by nano-feature, anti-thrombotic activity, thrombolytic activity, thrombus target and targeting release. Results: In vivo 0.01 μmol/kg of MTCA-KKV formed nano-particles less than 100 nm in diameter, targeted thrombus, released anti-thrombotic and thrombolytic pharmacophores, prevented thrombosis and dissolved blood clots. Conclusion: Based on the profiles of targeting thrombus, targeting release, inhibiting thrombosis and dissolving blood clots MTCA-KKV is a promising nano-medicine.

Cite

CITATION STYLE

APA

Zhao, S., Li, Z., Huang, F., Wu, J., Gui, L., Zhang, X., … Zhao, M. (2019). Nano-scaled MTCA-KKV: For targeting thrombus, releasing pharmacophores, inhibiting thrombosis and dissolving blood clots in vivo. International Journal of Nanomedicine, 14, 4817–4831. https://doi.org/10.2147/IJN.S206294

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free